Dr. Pearlman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3 Parkcenter Dr.
Suite 100
Sacramento, CA 95825Phone+1 916-454-4861Fax+1 916-454-3603
Summary
- Dr. Joel Pearlman is an ophthalmologist in Sacramento, CA and is affiliated with multiple hospitals in the area, including Doctors Medical Center of Modesto, Mercy General Hospital, Sutter Medical Center, Sacramento, and Sutter Roseville Medical Center. He received his medical degree from Baylor College of Medicine and has been in practice 22 years. He specializes in retinal disease and is experienced in retina surgery, vitreoretinal disease, and uveitis and ocular immunology.
Education & Training
- Johns Hopkins UniversityResidency, Ophthalmology, 1996 - 1999
- Sinai Hospital of BaltimoreInternship, Internal Medicine, 1995 - 1996
- Baylor College of MedicineClass of 1995
Certifications & Licensure
- CA State Medical License 2002 - 2026
- MD State Medical License 1999 - 2003
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD Start of enrollment: 2006 Apr 01
- Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD Start of enrollment: 2015 Jul 01
Publications & Presentations
PubMed
- 5 citationsRandomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.Anat Loewenstein, Norbert Czumbel, Jan Ernest, Jaroslava Dusová, Joel Pearlman
Ophthalmology. Retina. 2023-09-01 - 325 citationsRetinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s diseaseYosef Koronyo, David Biggs, Ernesto Barron, David S. Boyer, Joel A. Pearlman
JCI Insight. 2017-08-17 - 241 citationsC5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.Glenn J. Jaffe, Keith Westby, Karl G. Csaky, Jordi Monés, Joel A. Pearlman
Ophthalmology. 2021-04-01
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: